264 related articles for article (PubMed ID: 35433474)
21. Cross-Talk of Multiple Types of RNA Modification Regulators Uncovers the Tumor Microenvironment and Immune Infiltrates in Soft Tissue Sarcoma.
Qi L; Zhang W; Ren X; Xu R; Yang Z; Chen R; Tu C; Li Z
Front Immunol; 2022; 13():921223. PubMed ID: 35860263
[TBL] [Abstract][Full Text] [Related]
22. Characterization of tumor microenvironment and programmed death-related genes to identify molecular subtypes and drug resistance in pancreatic cancer.
Yu L; He R; Cui Y
Front Pharmacol; 2023; 14():1146280. PubMed ID: 37007021
[No Abstract] [Full Text] [Related]
23. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma.
Xue S; Ge W; Wang K; Mao T; Zhang X; Xu H; Wang Y; Yao J; Li S; Yue M; Ma J; Wang Y; Shentu D; Cui J; Wang L
Front Cell Dev Biol; 2022; 10():942225. PubMed ID: 36003146
[TBL] [Abstract][Full Text] [Related]
24. A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma.
Wang H; Tian RF; Liang X; Fan J; Duan ZC; Fan XY; Zhang JJ; Yao DS; Chen ZN; Li L
Front Oncol; 2022; 12():1015042. PubMed ID: 36713541
[TBL] [Abstract][Full Text] [Related]
25. Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma.
Li L; Xiao Z; He P; Zou W; Deng Z; Zhang G; Liu R
BMC Gastroenterol; 2022 Nov; 22(1):454. PubMed ID: 36371178
[TBL] [Abstract][Full Text] [Related]
26. Modeling of new markers for the diagnosis and prognosis of pancreatic cancer based on the transition from inflammation to cancer.
Zhou Y; Huang B; Zhang Q; Yu Y; Xiao J
Transl Cancer Res; 2024 Mar; 13(3):1425-1442. PubMed ID: 38617519
[TBL] [Abstract][Full Text] [Related]
27. The expression of m
Yao Y; Luo L; Xiang G; Xiong J; Ke N; Tan C; Chen Y; Liu X
Gland Surg; 2022 Jan; 11(1):147-165. PubMed ID: 35242677
[TBL] [Abstract][Full Text] [Related]
28. m
Yuan B; Qin H; Zhang J; Zhang M; Yang Y; Teng X; Yu H; Huang W; Wang Y
Front Oncol; 2022; 12():1087753. PubMed ID: 36591468
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
30. Expression, oncological and immunological characterizations of BZW1/2 in pancreatic adenocarcinoma.
Ge J; Mu S; Xiao E; Tian G; Tao L; Li D
Front Genet; 2022; 13():1002673. PubMed ID: 36267402
[No Abstract] [Full Text] [Related]
31. Mitophagy-mediated molecular subtypes depict the hallmarks of the tumour metabolism and guide precision chemotherapy in pancreatic adenocarcinoma.
Chen H; Zhang J; Sun X; Wang Y; Qian Y
Front Cell Dev Biol; 2022; 10():901207. PubMed ID: 35938160
[No Abstract] [Full Text] [Related]
32. Development and validation of a novel 3-gene prognostic model for pancreatic adenocarcinoma based on ferroptosis-related genes.
Yang J; Wei X; Hu F; Dong W; Sun L
Cancer Cell Int; 2022 Jan; 22(1):21. PubMed ID: 35033072
[TBL] [Abstract][Full Text] [Related]
33. RNA m
Zhang Q; Sun X; Sun J; Lu J; Gao X; Shen K; Qin X
Front Immunol; 2022; 13():905057. PubMed ID: 36389669
[TBL] [Abstract][Full Text] [Related]
34. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
35. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients.
Huang Y; Liu J; Zhu X
Digit Health; 2022; 8():20552076221133699. PubMed ID: 36312851
[TBL] [Abstract][Full Text] [Related]
36.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
37. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
38. Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study.
Wu G; Deng Z; Jin Z; Wang J; Xu B; Zeng J; Peng M; Wen Z; Guo Y
Biomed Res Int; 2020; 2020():1346045. PubMed ID: 32596278
[TBL] [Abstract][Full Text] [Related]
39. Expression pattern and prognostic value of circadian clock genes in pancreatic adenocarcinoma.
Zhang LL; He QK; Lv YN; Zhang ZJ; Xiang YK
Chronobiol Int; 2021 May; 38(5):681-693. PubMed ID: 33691542
[TBL] [Abstract][Full Text] [Related]
40. Systematic Analysis of an Invasion-Related 3-Gene Signature and Its Validation as a Prognostic Model for Pancreatic Cancer.
Xu D; Wang Y; Zhang Y; Liu Z; Chen Y; Zheng J
Front Oncol; 2021; 11():759586. PubMed ID: 34976806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
